A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels
Authors' conclusion
Angiographically derived RWS has the potential to predict the angiographic and clinical outcomes of DCB treatment for de novo SVD
Study context
- Population
- De novo small vessel disease treated with paclitaxel-coated balloon or plain old balloon angioplasty (POBA)
- Participants
- 260 participants266 lesions
- Comparison
- RWSmax ≥13% vs RWSmax <13% in DCB-treated lesions
- Primary endpoint
- In-segment late lumen loss (LLL)
- Follow-up
- 9-month follow-up
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
In-segment LLL, DCB group · 9 months
P = 0.0009
Further findings
RWSmax ≥13% vs RWSmax <13%
Binary restenosis, DCB group
P = 0.0040
Target lesion failure, DCB group
P = 0.022
DCB vs POBA
In-segment LLL in lesions with RWSmax ≥13% (subgroup), DCB vs POBA · no significant difference
P = 0.49
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels. EuroIntervention. Published 20 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →